ArticleAnnals of hematology2024

A real-life study of daratumumab-bortezomib-dexamethasone (D-VD) in lenalidomide exposed/refractory multiple myeloma patients: a report from the Triveneto Myeloma Working Group.

Gregorio Barilà et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.